Auriga Raises PT on DepoMed to $8

Symbols: DEPO
Tags: Auriga
Share

Auriga has raised the price target on DepoMed (NASDAQ: DEPO) from $7 to $8 and maintains its Buy rating.


 
 
< Previous
Piper Jaffray Lowers PT on Trius Therapeutics to $13
Next >
Evercore Partners Downgrades State Street to Equal-weight
Share
Printer-friendly version
Send to friend
We're Loving

Benzinga's Premium Memberships

Benzinga's News Delivered Free

Brain Trust